Roble, Belko & Company, Inc Precigen, Inc. Call Options Transaction History
Roble, Belko & Company, Inc
- $634 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PGEN
# of Institutions
143Shares Held
159MCall Options Held
232KPut Options Held
69K-
Third Security, LLC83.5MShares$75.1 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD17.9MShares$16.1 Million0.92% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.9MShares$9.78 Million0.02% of portfolio
-
Black Rock Inc. New York, NY10.2MShares$9.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$7.5 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $187M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...